See more : PMV Consumer Acquisition Corp. (PMVC) Income Statement Analysis – Financial Results
Complete financial analysis of Enliven Therapeutics, Inc. (ELVN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Enliven Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- QNB Finansbank A.S. (QNBFB.IS) Income Statement Analysis – Financial Results
- Kowloon Development Company Limited (0034.HK) Income Statement Analysis – Financial Results
- Future Vision II Acquisition Corp. (FVN) Income Statement Analysis – Financial Results
- Bristol-Myers Squibb Company (BMY) Income Statement Analysis – Financial Results
- Grovy India Limited (GROVY.BO) Income Statement Analysis – Financial Results
Enliven Therapeutics, Inc. (ELVN)
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 297.00K | 622.00K | 99.00K | 97.00K | 33.00K | 0.00 | 0.00 |
| Gross Profit | -297.00K | -622.00K | -99.00K | -97.00K | -33.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 64.57M | 31.02M | 20.47M | 8.24M | 19.01M | 8.24M | 7.92M |
| General & Administrative | 18.96M | 7.77M | 4.29M | 1.08M | 5.11M | 2.44M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | -33.00K | 0.00 | 0.00 |
| SG&A | 18.96M | 7.77M | 4.29M | 1.08M | 5.07M | 2.44M | 987.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | -9.68M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 83.53M | 38.79M | 24.76M | 9.32M | 24.08M | 10.68M | 8.91M |
| Cost & Expenses | 83.53M | 38.79M | 24.76M | 9.32M | 24.12M | 10.68M | 8.91M |
| Interest Income | 11.97M | 1.13M | 22.00K | 31.00K | 578.00K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 297.00K | 215.00K | 115.00K | 97.00K | 33.00K | -660.00K | 0.00 |
| EBITDA | -81.93M | -38.58M | -24.65M | -9.27M | -23.43M | -11.34M | 221.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -83.53M | -38.79M | -24.76M | -9.32M | -24.12M | -10.68M | -8.91M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 11.95M | 1.13M | 22.00K | -9.65M | 653.00K | -660.00K | 9.13M |
| Income Before Tax | -71.58M | -37.66M | -24.74M | -18.97M | -23.46M | -11.34M | 221.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 88.00K | -22.00K | -31.00K | 653.00K | -821.14K | 221.00K |
| Net Income | -71.58M | -37.75M | -24.72M | -18.94M | -23.46M | -11.34M | 0.00 |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.01 | -6.03 | -3.17 | -14.14 | -5.43 | -2.62 | 0.00 |
| EPS Diluted | -2.01 | -6.03 | -3.17 | -14.14 | -5.43 | -2.62 | 0.00 |
| Weighted Avg Shares Out | 35.55M | 6.25M | 7.81M | 3.48M | 4.32M | 4.32M | 4.32M |
| Weighted Avg Shares Out (Dil) | 35.55M | 6.25M | 7.81M | 3.48M | 4.32M | 4.32M | 4.32M |
Imara Announces the Appointment of Lynette Hopkinson as Senior Vice President of Regulatory
Brings 25 years of experience in the pharmaceutical and biotech industries and a deep understanding of global regulatory strategy and commercial regulatory affairs Brings 25 years of experience in the pharmaceutical and biotech industries and a deep understanding of global...
IMARA Inc.'s (IMRA) CEO Rahul Ballal on Q3 2020 Results - Earnings Call Transcript
IMARA Inc.'s (IMRA) CEO Rahul Ballal on Q3 2020 Results - Earnings Call Transcript
Imara Reports Third Quarter 2020 Financial Results and Business Highlights
Patient Dosing Underway in Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia
Imara to Webcast Conference Call of Third Quarter Financial Results
BOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company will host...
Thalassemia Treatment Market Size, 2020 Growth, Types, Trends, Size, Share and Top Key Players by Forecast Research 2025
Oct 06, 2020 (Heraldkeepers) -- Global Thalassemia Treatment Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2019-2025. Rise in...
U.S. IPO Week Ahead: No IPOs, But Plenty Of Potential Launches In The Short Holiday Week
Just one SPAC is scheduled for the week ahead. More SPACs may join the IPO calendar, and another wave of new filings will likely hit after Labor Day as well.
Wall Street Breakfast: The Week Ahead
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
Stocks To Watch: Tech Reboots And Eyes On Lululemon, Peloton & GameStop
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
TG Therapeutics Umbralisib Development, And Other News: The Good, Bad And Ugly Of Biopharma
TG Therapeutics reports development for Umbralisib. Mesoblast gets FDA nod for Ryoncil.
Source: https://incomestatements.info
Category: Stock Reports